Latest Biotech News

Gilead Sciences moved deeper into immunology by agreeing to acquire Ouro Medicines, a clinical-stage BCMA/CD3 bispecific developer, in a deal valued at about $2.17 billion. The acquisition centers...

Merck joined the growing list of pharma adopters of Quotient Therapeutics’ somatic genomics platform by signing a multi-year deal focused on inflammatory bowel disease target discovery. Merck will...

Sanofi expanded its autoimmune pipeline by licensing KT501, a tri-specific T-cell engager antibody candidate from Kali Therapeutics. The collaboration gives Sanofi exclusive worldwide rights and...

Karyopharm Therapeutics disclosed top-line Phase 3 results from its Sentry trial of Xpovio (selinexor) plus ruxolitinib in front-line myelofibrosis. The combination met the trial’s first...

At BIO-Europe Spring, executives from Lundbeck, Ipsen, Astellas, and others described how biotech dealmaking has shifted toward resilience-driven structuring amid geopolitical uncertainty....

Discovery Life Sciences partnered with Mindpeak to apply AI-assisted tissue biomarker analysis across clinical trial workflows and translational research. The collaboration aims to reduce...

RyboDyn raised $10 million in seed funding to accelerate oncology target discovery by exploring the “dark proteome,” the pool of understudied peptides and protein products not captured in standard...

Verana Health and Guardant Health announced a partnership to provide biopharma researchers with combined precision medicine data access using Verana’s regulatory-grade therapeutic-specific...

Aardvark Therapeutics said it is pausing two Phase 2 trials of its oral obesity asset ARD-201, putting its entire metabolic pipeline on hold. The company cited a comprehensive review of ARD-201...

The FDA issued a warning to ImmunityBio over what it described as false and misleading claims about Anktiva in a TV advertisement and a podcast. The agency said the messaging created a misleading...

Gilead Sciences agreed to acquire Ouro Medicines in a deal valued at about $2.17 billion, adding the company’s BCMAxCD3 T-cell engager gamgertamig (OM336) to Gilead’s autoimmune pipeline. The...

Sanofi agreed to license Kali Therapeutics’ lead tri-specific T-cell engager KT501, gaining exclusive worldwide rights to the CD3-masked antibody program with upfront and milestone payments...

Merck agreed to use Quotient Therapeutics’ somatic genomics platform to identify new drug targets for inflammatory bowel disease, marking Quotient’s latest expansion beyond earlier collaborations....

Karyopharm reported mixed Phase 3 results from its Sentry trial of selinexor (Xpovio) plus ruxolitinib in front-line myelofibrosis and said it plans to meet the FDA about a potential supplemental...

University of Pennsylvania researchers reported redesigned lipid nanoparticles that shift mRNA delivery away from the liver and toward lymph nodes in vivo. The work, published in the Journal of...

Roche announced CE marking for its cobas Eplex respiratory pathogen panel 3 (RP3), bringing a molecular test that simultaneously detects and differentiates up to 25 respiratory targets. The assay...

Discovery Life Sciences and Mindpeak partnered to streamline clinical trial biomarker workflows using AI-assisted tissue analysis. The collaboration is designed to reduce variability in...

The World Health Organization called for urgent scale-up of near point-of-care tuberculosis diagnostics, including a new class of nPOC molecular testing, ahead of World Tuberculosis Day. WHO’s...

A growing set of women’s health companies is developing noninvasive multiomics tests aimed at earlier endometriosis diagnosis, leveraging menstrual blood as the primary biosample. The current...

A survey of 1,500 Portuguese researchers found that more than 90% admitted to questionable research behaviors, signaling a widespread “grey zone” ethics problem. The practices ranged from...